Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Director | January 23, 2025 | January 24, 2025 |
| uniQure N.V.QURE · Entity 4162 | Chief Medical Officer | June 06, 2018 | June 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cadrenal Therapeutics, Inc.
Report date January 23, 2025 · Filed January 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $19.79 · Expires 2035-01-22 | Direct | 20,000 |
Reported balance
After 2025-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-23 · Grant · Acquired 20,000 · Balance 20,000 F1: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025.
uniQure N.V.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 159,458 |
Reported balance
After 2018-06-06 transaction · row 1
1 source rowRow 1 · 2018-06-06 · Sale · Disposed 23,929 · Balance 159,458 F1: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2: The price reported in Column 4 is a weighted average price. 23,829 of such shares were sold in multiple transactions at prices ranging from $36.70 to $37.69, and 100 of such shares were sold at $37.73. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
F2: The price reported in Column 4 is a weighted average price. 23,829 of such shares were sold in multiple transactions at prices ranging from $36.70 to $37.69, and 100 of such shares were sold at $37.73. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2028-08-20 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2025 Filed Jan 24, 2025 18:12 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006638 · ownership.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:41 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005004 · ownership.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:17 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 200,000 | Not disclosed Strike: $2.18 | Not disclosed |
DisclosureSEC source: 0001562180-20-000679 · primarydocument.xml · derivative · entry 2 Zelenkofske Steven · CIK 0001578333 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:17 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.49 | Not disclosed |
DisclosureSEC source: 0001562180-20-000679 · primarydocument.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2028-08-20 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:51 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-19-005374 · doc4.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 18:25 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee stock option · Derivative | 500,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001209191-18-047839 · doc4.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 08:58 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 23,929 | $37.14 | $888,723.06 |
DisclosureSEC source: 0000904454-18-000405 · edgar.xml · nonDerivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,458 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. 23,829 of such shares were sold in multiple transactions at prices ranging from $36.70 to $37.69, and 100 of such shares were sold at $37.73. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 12:02 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 22,364 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000904454-18-000082 · edgar.xml · derivative · entry 2 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,364 Underlying: Ordinary Shares · 22,364 shares Expires 2028-01-26 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 12:02 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,387 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000082 · edgar.xml · nonDerivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,387 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 16:34 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038308 · doc4.xml · nonDerivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.